TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2817306

Group type: EXPERIMENTAL
Intervention: Hyposensitization (HS) with unmodified Dp-extract
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hyposensitization (HS) with mPEG modified Dp-extract
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (Ctls)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hyposensitization (HS) groups
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with improved pulmonary symptoms
Number of subjects: 46
Study: 5565516

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 272

Group type: COMPARATOR
Intervention: I.U.D.
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (stopped or changed)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Oral contraceptives (remained on the same)
Number of subjects: 272
Study: 31625599

Group type: EXPERIMENTAL
Intervention: Empirical likelihood estimate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lagrange multiplier (LM) test
Number of subjects: 0
Study: 29999201

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (1.25 × 10^8 bacteria/day)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 29197913

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography
Number of subjects: 34

Group type: COMPARATOR
Intervention: Surgeon's anatomic knowledge (Control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography (performed by a single surgeon)
Number of subjects: 34
Study: 25286317

Group type: EXPERIMENTAL
Intervention: Different piece of fruit selected in the afternoon after a morning selection of fruit (Study 1)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Different piece of fruit selected in the afternoon after a morning selection of fruit (Study 2)
Number of subjects: 375
Study: 22738315

Group type: EXPERIMENTAL
Intervention: Microencapsulated sodium butyrate (MSB)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 21810307

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzimidazoles
Number of subjects: 0
Study: 19387704

Group type: EXPERIMENTAL
Intervention: Bupivacaine and methylprednisolone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 150
Study: 16751034

Group type: EXPERIMENTAL
Intervention: Ahmed shunt
Number of subjects: 118

Group type: COMPARATOR
Intervention: Baerveldt shunt
Number of subjects: 118
Study: 14628495

Group type: EXPERIMENTAL
Intervention: 50 mg/24 h DHEA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11140558

Group type: EXPERIMENTAL
Intervention: SRP+gel (subgingival scaling plus 25% metronidazole gel)
Number of subjects: 88

Group type: COMPARATOR
Intervention: SRP (subgingival scaling)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: SRP+gel
Number of subjects: 88

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 88
Study: 9167457

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg twice a day)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 1345409

Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 3897082

Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg t.i.d.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ephedrine 50 mg t.i.d.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 29895502

Group type: EXPERIMENTAL
Intervention: Live-attenuated Suvaxyn® CSF Marker vaccine (CP7_E2alf), administered intramuscularly on day 44 of gestation.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Unvaccinated control group (2 sows).
Number of subjects: 8
Study: 27722837

Group type: EXPERIMENTAL
Intervention: Attention training (8 sessions)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Combat-exposed veterans without PTSD (n=12)
Number of subjects: 14
Study: 24388126

Group type: EXPERIMENTAL
Intervention: Group-based intervention consisting of two motivational interviewing-guided group sessions led by a pharmacist
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group received brochures about their DMARDs
Number of subjects: 123
Study: 23579894

Group type: EXPERIMENTAL
Intervention: Cocured ultrathin flowable composite lining (0.5‐1mm) with overlying composite (Group II)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cocured thin lining (1‐1.5mm) with overlying composite (Group III)
Number of subjects: 50

Group type: COMPARATOR
Intervention: P60 filling alone (Group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Precuring ultrathin lining (0.5‐1 mm) (Group IV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Precuring thin lining (1‐1.5) (Group V)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cocured specimens (Groups II and III)
Number of subjects: 50
Study: 19830558

Group type: EXPERIMENTAL
Intervention: Probiotics (Bacillus subtilis and Streptococcus faecium) for 2 weeks with oral sodium phosphate (NaP)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo with oral sodium phosphate (NaP)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Probiotics (Bacillus subtilis and Streptococcus faecium)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 18504612

Group type: EXPERIMENTAL
Intervention: IV ibandronic acid 6 mg infused over 15 min every 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ibandronic acid 50 mg/day
Number of subjects: 0
Study: 16766588

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.75 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Ondansetron 32 mg
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg with dexamethasone
Number of subjects: 667
Study: 12869893

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 13-15 mg/kg/d
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 12201317

Group type: EXPERIMENTAL
Intervention: New generation of SSR antidepressants
Number of subjects: 0
Study: 7745318

Group type: EXPERIMENTAL
Intervention: CO2 laser haemorrhoidectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy
Number of subjects: 0
Study: 2345592

Group type: EXPERIMENTAL
Intervention: Enalapril and sodium restriction
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium restriction
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril and hydrochlorothiazide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril and nifedipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 16
Study: 6780998

Group type: EXPERIMENTAL
Intervention: 96 mg of inhaled cocaine
Number of subjects: 8

Group type: COMPARATOR
Intervention: No cocaine (control)
Number of subjects: 8
Study: 31599168

Group type: EXPERIMENTAL
Intervention: Group counselling (4 weekly sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study: 31520480

Group type: EXPERIMENTAL
Intervention: Combination treatment with porous tantalum rod implantation and intra-arterial infusion of peripheral blood stem cells (PBSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pain management (control group)
Number of subjects: 0
Study: 31218866

Group type: EXPERIMENTAL
Intervention: Ceramic onlay
Number of subjects: 60

Group type: COMPARATOR
Intervention: Resin composite
Number of subjects: 60
Study: 28489182

Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise (cycle ergometer for lower limbs, 30 minutes, 60-70% of maximal heart rate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study: 26790202

Group type: EXPERIMENTAL
Intervention: Deep acupuncture (group A) at Lianquan (CV 23) with a depth of 60-70 mm
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Shallow acupuncture (group B) at Lianquan (CV 23) with a depth of 30-40 mm
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Glossopharyngeum acupuncture (group C)
Number of subjects: 251
Study: 23467073

Group type: EXPERIMENTAL
Intervention: Chlorella supplementation
Number of subjects: 18
Study: 21299472

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19755916

Group type: EXPERIMENTAL
Intervention: RRR‐alpha‐TOH (750 IU/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16790655

Group type: EXPERIMENTAL
Intervention: Intravenous small-dose morphine (4 mg/70 kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 15799917

Group type: EXPERIMENTAL
Intervention: Incor LVAD
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Excor LVAD
Number of subjects: 13
Study: 11590633

Group type: EXPERIMENTAL
Intervention: Intervention allocation k' or k'(s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Score test or skewness-corrected score test
Number of subjects: 0
Study: 9734695

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LoDAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study: 7917367

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 122
Study: 2550700

Group type: EXPERIMENTAL
Intervention: CMV‐HIGP (2 ml per kg body weight one time in four weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CMV‐HIGP (1 ml per kilogram of body weight) every two to three weeks initially, with double dose for basic immunisation protection
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 85
Study: 8980

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate with trisulfapyrimidines
Number of subjects: 383

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 383

Group type: COMPARATOR
Intervention: Erythromycin estolate
Number of subjects: 383
Study: 7240435

Group type: EXPERIMENTAL
Intervention: meperidine plus chlorpromazine
Number of subjects: 10

Group type: COMPARATOR
Intervention: meperidine plus placebo
Number of subjects: 10
Study: 31344403

Group type: EXPERIMENTAL
Intervention: Admission TRPG measurement
Number of subjects: 469

Group type: COMPARATOR
Intervention: Lower TRPG
Number of subjects: 469
Study: 30019498

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg once daily for 24 weeks
Number of subjects: 613

Group type: COMPARATOR
Intervention: dapagliflozin 5 mg titrated to 10 mg once daily for 24 weeks
Number of subjects: 613
Study: 27163985

Group type: EXPERIMENTAL
Intervention: Intervention group (different order for second reading)
Number of subjects: 1194147

Group type: COMPARATOR
Intervention: Control group (same order for second reading)
Number of subjects: 1194147

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1194147

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1194147
Study: 24988105

Group type: EXPERIMENTAL
Intervention: Access to outdoor areas
Number of subjects: 6261

Group type: EXPERIMENTAL
Intervention: Access to workout facilities within a worksite
Number of subjects: 6261

Group type: EXPERIMENTAL
Intervention: Presence of a cafeteria and fewer vending machines
Number of subjects: 6261

Group type: EXPERIMENTAL
Intervention: Better eating habits
Number of subjects: 6261

Group type: EXPERIMENTAL
Intervention: Meeting physical activity recommendations
Number of subjects: 6261
Study: 22253279

Group type: EXPERIMENTAL
Intervention: Uncoated drug-free mini-tablets 2 mm in diameter
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 ml of glucose syrup 15%
Number of subjects: 60
Study: 19952869

Group type: EXPERIMENTAL
Intervention: Sensitivity training for parents in the NICU (10 sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no sensitivity training)
Number of subjects: 45
Study: 17004240

Group type: EXPERIMENTAL
Intervention: RF operators
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 16309081

Group type: EXPERIMENTAL
Intervention: Acupuncture at corresponding acupoints at the healthy side for acute stage (26 cases)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Acupuncture at the affected side with shallow needling method for resting stage (15 cases)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Routine acupuncture and moxibustion for restoration stage (2 cases)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Routine acupuncture and moxibustion (control group, 36 cases)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Treatment group (all methods combined)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (routine acupuncture and moxibustion)
Number of subjects: 79
Study: 12170406

Group type: EXPERIMENTAL
Intervention: Olympus push enteroscope SIF‐100 (working length 2200 mm)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Olympus push enteroscope SIF‐Q140 (working length 2500 mm)
Number of subjects: 28
Study: 10213294

Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal lungs)
Number of subjects: 0
Study: 7885264

Group type: EXPERIMENTAL
Intervention: Odd-even status of numbers
Number of subjects: 0
Study: 2100986

Group type: EXPERIMENTAL
Intervention: Prism adaptation with augmented surgery
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Prism adaptation with conventional surgery
Number of subjects: 188

Group type: COMPARATOR
Intervention: No prism adaptation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Overall effect of prism adaptation
Number of subjects: 188
Study: 27127

Group type: EXPERIMENTAL
Intervention: 0.4 mg Pindolol (Visken)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no beta blocker treatment)
Number of subjects: 10
Study: 31800462

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1%
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.5%
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Active metabolite amfenac
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 104
Study: 30906317

Group type: EXPERIMENTAL
Intervention: Deception group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Honesty group
Number of subjects: 15
Study: 28148667

Group type: EXPERIMENTAL
Intervention: Push Ortho Thumb Brace CMC
Number of subjects: 63

Group type: COMPARATOR
Intervention: Custom-made orthosis
Number of subjects: 63
Study: 25514804

Group type: EXPERIMENTAL
Intervention: Afatinib (≤50 mg daily, monotherapy)
Number of subjects: 69
Study: 23616386

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus (D.p.) and Dermatophagoides farina (D.f.) extract (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Matched placebo controls (n = 60)
Number of subjects: 120
Study: 22038349

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide inhalation (18 μg/day)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Doxofylline oral tablets (0.2 g/time, 2 times a day)
Number of subjects: 127
Study: 19271232

Group type: EXPERIMENTAL
Intervention: Eccentric strengthening programme for 8 weeks
Number of subjects: 22
Study: 17046260

Group type: EXPERIMENTAL
Intervention: Trip recovery training on a modified treadmill
Number of subjects: 12

Group type: COMPARATOR
Intervention: Walking on a treadmill for 15 min (Control)
Number of subjects: 12
Study: 14722166

Group type: EXPERIMENTAL
Intervention: Management algorithm based on near-patient tests (Hepcon, thromboelastography, PFA-100)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Management algorithm based on laboratory tests (rapidly available laboratory clotting tests)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Clinician discretion (retrospective case-control group, n=108)
Number of subjects: 102
Study: 11289326

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) aqueous nasal spray, 200 microg for adults and 100 microg for pediatric patients.
Number of subjects: 3605

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) aqueous nasal spray
Number of subjects: 3605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3605
Study: 9421852

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nontransfused patients
Number of subjects: 56
Study: 7508331

Group type: EXPERIMENTAL
Intervention: Alfuzosin (2.5 mg tid)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Prazosin (2 mg bid)
Number of subjects: 103
Study: 3735627

Group type: EXPERIMENTAL
Intervention: Educational program discussing acceptable indications for x-ray pelvimetry
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 120
Study: 31527463

Group type: EXPERIMENTAL
Intervention: Intramedullary self-locked plates
Number of subjects: 24

Group type: COMPARATOR
Intervention: Herbert screws
Number of subjects: 24
Study: 28314639

Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk chocolate
Number of subjects: 0
Study: 26211516

Group type: EXPERIMENTAL
Intervention: Shakuyakukanzoto (SKT) 2.5 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shakuyakukanzoto (SKT) 5.0 g/day
Number of subjects: 0
Study: 24072003

Group type: EXPERIMENTAL
Intervention: Trevo device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Merci device
Number of subjects: 0
Study: 21669961

Group type: EXPERIMENTAL
Intervention: 200 mg alagebrium twice daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18647853

Group type: EXPERIMENTAL
Intervention: Tablet PC self-administered questionnaires
Number of subjects: 153
Study: 16151771

Group type: EXPERIMENTAL
Intervention: [123I]Mtr-TOCA
Number of subjects: 6

Group type: COMPARATOR
Intervention: [111In]OC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: [123I]Mtr-TOCA and [111In]OC
Number of subjects: 6
Study: 12932064

Group type: EXPERIMENTAL
Intervention: Sufentanil 2.5 microg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 5.0 microg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg
Number of subjects: 80

Group type: COMPARATOR
Intervention: No sufentanil (Control Group 1)
Number of subjects: 80
Study: 10744202

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide 2% (Trusopt) three times daily for three days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral acetozolamide (Diazomide) 250 mg three times daily for three days
Number of subjects: 62
Study: 8774390

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous 1 alpha(OH)D3 treatment for > 300 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intermittent oral 1 alpha(OH)D3 treatment for 100 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Reinstatement of intermittent intravenous 1 alpha(OH)D3 treatment for another 100 days
Number of subjects: 26
Study: 1727741

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg (b.i.d.)
Number of subjects: 18
Study: 6653133

Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg) plus metoclopramide (5 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Paracetamol (500 mg) alone
Number of subjects: 39
Study: 31843183

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration with particulate xenogenic bone substitutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guided bone regeneration with particulate xenogenic bone substitutes and autogenous block grafts
Number of subjects: 0
Study: 30134971

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26350667

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 30 mg b.i.d.
Number of subjects: 34
Study: 23870610

Group type: EXPERIMENTAL
Intervention: Oral ticagrelor (400 mg daily) for 6 days followed by oral midazolam (7.5 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (2.5 mg) after ticagrelor (270 mg single dose, then 180 mg BID for 6 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 20689452

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (AO leg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 16
Study: 19775041

Group type: EXPERIMENTAL
Intervention: Lactated solution (Hartmann's solution; anions: chloride 109 mmol/l, lactate 29 mmol/l)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chloride-only solution (Ringer's Injection; anions: chloride 152 mmol/l)
Number of subjects: 20
Study: 17106320

Group type: EXPERIMENTAL
Intervention: A&D UB‐511 (UB‐512) device for self-measurement of blood pressure
Number of subjects: 85
Study: 15561385

Group type: EXPERIMENTAL
Intervention: GW‐1000‐02 (Sativex), containing Delta(9)tetrahydrocannabinol (THC):cannabidiol (CBD) in an approximate 1:1 ratio
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GW‐2000‐02, containing primarily THC
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11403724

Group type: EXPERIMENTAL
Intervention: Novel smoking system
Number of subjects: 32

Group type: COMPARATOR
Intervention: Own brand of cigarettes
Number of subjects: 32

Group type: COMPARATOR
Intervention: Marketed brand that was not their own
Number of subjects: 32

Group type: COMPARATOR
Intervention: De-nicotinized tobacco cigarettes
Number of subjects: 32
Study: 8213583

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once daily at bedtime
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062